Controlled release of human growth hormone in rats following parenteral administration of poloxamer gels

Journal of Controlled Release

Volumn 49, Issue 1, 1997, Pages 21-26

  Katakam, Manohar ^a   Ravis, William R ^a   Banga, Ajay K ^a  

^a School of Pharmacy   (United States)

Author keywords

Controlled release; Human growth hormone; Parenteral delivery; Poloxamers; Rat study

Indexed keywords

HUMAN GROWTH HORMONE; IODINE 125; POLOXAMER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MANUFACTURE; DRUG RELEASE; DRUG URINE LEVEL; GEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; INTRAMUSCULAR DRUG ADMINISTRATION; IODINATION; ISOTOPE LABELING; LIQUID SCINTILLATION COUNTING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; SUSTAINED RELEASE FORMULATION;

EID: 0030826964     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(97)01648-9     Document Type: Article

References (18)

1. R. Pearlman and T.A. Bewley, in: Y.J. Wang and R. Pearlman (Eds.) Pharmaceutical Biotechnology (Series editor, R.T. Borchardt) Vol. 5: Stability and characterization of protein and peptide drugs: Case histories, Plenum Press, New York, 1993, p. 1.
2. A.K. Banga, Therapeutic Peptides and Proteins: Formulation, Processing, and Delivery Systems, Technomic, Lancaster, PA, 1996.
3. M.O. Groesbeck and A.F. Parlow, Highly improved precision of the hypophysectomized female rat body weight gain bioassay for growth hormone by increased frequency of injections, avoidance of antibody formation and other simple modifications, Endocrinology 120 (1987) 2582-2590.
4. K.W. Kastrup, J. Sandahl-Christriansen and J.O.K. Andersen, Increased growth rate following transfer to daily subcutaneous administration from three weekly intramuscular injections of human growth hormone to deficient children, Acta Endocrinol. (Copenhagen) 104 (1983) 148-152.
5. M.J. Poznansky, J. Halford and D. Taylor, Growth hormone-albumin conjugates: reduced renal toxicity and altered plasma clearance, FEBS Lett. 239 (1988) 18-22.
6. T.P. Johnston and S.C. Miller, Toxicological evaluation of poloxamer vehicles for intramuscular use, J. Parent. Sci. Technol. 39 (1985) 83-88.
7. T.P. Johnston, M.A. Punjabi and C.J. Froelich, Sustained delivery of interleukin-2 from a poloxamer 407 gel matrix following intraperitoneal injection in mice, Pharm. Res. 9 (1992) 425-434.
8. K.A. Fults and T.P. Johnston, Sustained-release of urease from a poloxamer gel matrix, J. Parent. Sci. Technol. 44 (1990) 58-65.
9. P.L. Wang and T.P. Johnston, Sustained-release interleukin-2 following intramuscular injection in rats. Int. J. Pharm. 113 (1995) 73-81.
10. M. Katakam, L.N. Bell and A.K. Banga, Effect of surfactants on the physical stability of recombinant human growth hormone, J. Pharm. Sci. 84 (1995) 713-716.
11. BASF Wyandotte Corp., Technical data on Pluronic polyols, OS796, Wyandotte, MI, 1975 (unpublished).
12. P.R. Byron and E. Notari, Clinical analysis of the 'flip-flop' phenomenon in the two-compartment pharmacokinetic model, J. Pharm. Sci. 65 (1976) 1140.
13. K. Wakai, T. Sushima, O. Isozaki, K. Sato and K. Shizome, Processing of rhGH by rat hepatocytes in monolayer culture, Endocrinology 114 (1984) 1475-1482.
14. P. Roupas and A.C. Herington, Processing of rhGH by rat adipocytes in primary culture: differentiation between release of intact hormone and degradative processing, Endocrinology 121 (1987) 1521-1530.
15. F. Bullier-Picard, M.C. Postel-Vinay and C. Kayser, In-vivo uptake of rhGH in male rat liver, J. Endocrinol. 121 (1989) 19-25.
16. M. Katakam, W.R. Ravis, D.L. Golden and A.K. Banga, Controlled release of human growth hormone following subcutaneous administration in dogs, Int. J. Pharm. 152 (1997) 530-58.
17. N. Gangrade and J.C. Price, Simple gas chromatographic head space analysis of residual organic solvent in microspheres, J. Pharm. Sci. 81 (1992) 201-202.
18. J.O.L. Jorgensen, T.L. Flyvbjerg, S. Orskov and C.J.S. Hristiansen, Subcutaneous degradation of biosynthetic human growth hormone in growth hormone deficient patients, Acta Endocrinol. (Copenhagen) 118 (1988) 115-158.